Short- and long-term effects of therapy with interferon-α and pegylated interferon-α/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 1, 2005, Pages 49-55

  Homoncik, M ^a   Ferlitsch, A ^a   Ferenci, P ^a   Formann, E ^a   Jilma, B ^a   Gangl, A ^a   Panzer, S ^a   Peck Radosavljevic, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALPHA INTERFERON; ALPHA2A INTERFERON; COLLAGEN; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; RIBAVIRIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CLOTTING TIME; BLOOD SAMPLING; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; PLATELET PLUG; PRIORITY JOURNAL; RISK FACTOR; SHORT COURSE THERAPY; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA;

ADULT; BLOOD PLATELETS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET COUNT; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RIBAVIRIN; VON WILLEBRAND FACTOR;

EID: 12944291471     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02305.x     Document Type: Article

References (37)

1. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: Management of Hepatitis C: 2002. Hepatology 2002; 36 (Suppl 1): 0S1-2.
2. Herrine SK. Approach to the patient with chronic hepatitis C virus infection. Ann Intern Med 2002; 136: 747-57.
3. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with Interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 22: 958-65.
4. Fried MW, Schiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
5. Dieterich DT, Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003; 15: 533-41.
6. Dusheiko G. Side effects of alpha Interferon in chronic hepatitis C. Hepatology 1997; 26(3 Suppl 1): 112-21S.
7. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002; 123: 141-51.
8. Peck-Radosavljevic M, Wichlas M, Pidlich J et al. Blunted thrombopoietin response to Interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998; 28: 1424-9.
9. Fattorutto M, Pradier O, Schmartz D, Ickx B, Barvais L. Does the platelet function analyser (PFA-100) predict blood loss after cardiopulmonary bypass? Br J Anaesth 2003; 90: 692-3.
10. Blanchette VS, Sparling C, Turner C. Inherited bleeding disorders. Baillieres Clin Hematol 1991; 4: 291-332.
11. Westerhout CM, Boersma E. Risk-benefit analysis of platelet glycoprotein inhibitors in acute coronary syndromes. Expert Opin Drug Saf 2003; 2: 49-58.
12. Harrison P, Robinson MS, Mackie IJ. et al Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis 1999; 10: 25-31.
13. Harrison P, Robinson M Liesner R, et al. The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction. Clin Lab Hematol 2002; 24: 225-32.
14. Eckman MH, Erban JK, Singh SK, Kao GS. Screening for the risk for bleeding or thrombosis. Ann Intern Med 2003; 138: 15-24.
15. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138: 152-63.
16. Cariappa R, Wilhite TR, Parvin CA, Luchtman-Jones L. Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems. J Pediatr Hematol Oncol 2003; 25: 474-9.
17. Troost MM, van Genderen PJ. Excessive prolongation of the Ivy bleeding time after aspirin in essential thrombocythemia is also demonstrable in vitro in the high shear stress system PFA-100. Ann Hematol 2002; 81: 353-4.
18. Zaccaria F, Dietrich W, Richter JA. In vitro bleeding time (PFA-100™) helps to identify patients with platelet dysfuction-dependent increased bleeding after coronary artery bypass grafting. Critical Care 2003; 7(Suppl 1): 12.
19. Favaloro EJ, Facey D, Henniker A. Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen for von Willebrand's disease and other disorders. Am J Hematol 1999; 62: 165-74.
20. Homoncik M, Blann AD, Hollenstein U, Pernerstorfer T, Eichler HG, Jilma B. Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol 2000; 111: 1250-2.
21. Savage B, Shattil SJ, Ruggeri ZM. Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb-IIIa (integrin alpha lib beta 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem 1992; 267: 11300-6.
22. Berndt MC, Shen Y, Dopheide SM, Gardiner EE, Andrews RK. The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Haemost 2001; 86: 178-88.
23. Ferenci P, Michael G, Laferl H, et al. Prospective evaluation of the 24 hour interferon-induced decline in hepatitis C virus genotype I load to predict response to peginterferon-alfa2a/ribavirin combination therapy. Gastroenterology 2003; 124 (Suppl 1): A767.
24. Rand ML, Carcao MD, Blanchette VS. Use of the PFA-100 in the assessment of primary, platelet-related hemostasis in a pediatric setting. Semin Thromb Hemost 1998; 24: 523-9.
25. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000; 83: 316-21.
26. De La Cadena RA, Majluf-Cruz A, Stadnicki A, et al. Recombinant tumor necrosis factor receptor p75 fusion protein (TNFR:Fc) alters endotoxin-induced activation of the kinin, flbrinolytic, and coagulation systems in normal humans. Thromb Haemost 1998; 80: 114-8.
27. Kreil A, Kobryn T, Wichlas M, et al. TNF-alpha, its soluble receptors and HCV kinetics during IFN-Induction therapy. Gastroenterology 2002; 123 (Suppl 1): 77.
28. Reiter RA, Mayr F, Blazicek H, et al. Desmopressin and platelets antagonize the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003; 102: 4594-9.
29. Mazzucconi MG, Ferrari A, Solinas S, et al. Studies of von Willebrand factor in essential thrombocythemia patients treated with alpha-2b recombinant interferon. Haemostasis 1991; 21: 135-40.
30. Stevens TR, James JP, Simmonds NJ, et al. Circulating von Willebrand factor in inflammatory bowel disease. Gut 1992; 33: 502-6.
31. Blann AD, Herrick A, Jayson MI. Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Br J Rheumatol 1995; 34: 814-9.
32. Ferro D, Quintarelli C, Lattuada A, et al. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 1996; 23: 1377-83.
33. Albornoz L, Alvarez D, Otaso JC, et al. Von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levels. J Hepatol 1999; 30: 451-5.
34. Beer JH, Clerici N, Baillod P, von Feiten A, Schlappritzi E, Buchi L. Quantitative and qualitative analysis of platelet GPIb and von Willebrand factor in liver cirrhosis. Thromb Haemost 1995; 73: 601-9.
35. Mannucci M, Canciani T, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98: 2730-5.
36. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000; 95: 2983-9.
37. Homoncik M, Jilma-Stohlawetz P, Schmid M, Ferlitsch A, Peck-Radosavljevic M. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis. A randomized, double blind, placebo controlled study. Aliment Pharmacol Ther 2004; 15: 437-43.